, Volume 32, Issue 3, pp 235–243 | Cite as

Cost–Utility Analysis of the Newly Recommended Adjuvant Chemotherapy for Resectable Gastric Cancer Patients in the 2011 Chinese National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology: Gastric Cancer

  • Tan Chongqing
  • Peng LiubaoEmail author
  • Zeng Xiaohui
  • Li Jianhe
  • Wan Xiaomin
  • Chen Gannong
  • Wang Siying
  • Ouyang Lihui
  • Zhao Ziying
Original Research Article



Postoperative adjuvant chemotherapy with capecitabine and oxaliplatin was first recommended for resectable gastric cancer patients in the 2011 Chinese National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology: Gastric Cancer, but the economic influence of this therapy in China is unknown.


The aim of the present study was to determine the cost-effectiveness of adjuvant chemotherapy with capecitabine and oxaliplatin after a gastrectomy with extended (D2) lymph-node dissection, compared with a D2 gastrectomy alone, for patients with stage II–IIIB gastric cancer.


On the basis of data from the CLASSIC trial, a Markov model was created to determine economic and clinical data for patients in the chemotherapy and surgery group (CSG) and the surgery-only group (SOG). The costs, presented in 2010 US dollars and estimated from the perspective of the Chinese health-care system, were obtained from the published literature and the local health system. The utilities were based on published literature. Costs, life years (LYs), quality-adjusted life years (QALYs), and incremental cost-effectiveness ratios (ICER) were estimated. A lifetime horizon and a 3 % annual discount rate were used. One-way and probabilistic sensitivity analyses were performed.


For the base case, the CSG compared with SOG would increase LYs and QALYs in a 3-, 5-, 10- or 30-year time horizon (except the QALYs at 3 or 5 years). In the short run (such as in 3 or 5 years), the medical costs would increase owing to adjuvant chemotherapy of capecitabine plus oxaliplatin after D2 gastrectomy, but in the long run the costs would decline. The ICERs suggested that the SOG was dominant at 3 or 5 years and the CSG was dominant at 10 or 30 years. The one-way sensitivity analysis showed that the utility of disease-free survival for 1–10 years for the SOG and the cost of oxaliplatin were the most influential parameters. The probabilistic sensitivity analysis predicted a 98.6 % likelihood that the ICER for the CSG would be less than US$13,527/QALY (three times the per capita gross domestic product of China).


For patients in China with resectable disease, our results suggest that adjuvant chemotherapy with capecitabine plus oxaliplatin after a D2 gastrectomy is cost-saving and dominant in the long run on the basis of a current clinical trial, compared with treatment with a D2 gastrectomy alone.


Gastric Cancer Overall Survival Oxaliplatin Capecitabine National Comprehensive Cancer Network 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.



The manuscript was supported by a grant from the National Natural Science Foundation of China (no. 81173028). All the authors have indicated that they have no conflicts of interest with regard to the content of article. Prof. Peng contributed to obtaining funding and the whole process. Dr. Tan contributed to the design of model, analysis of data and paper writing. Dr. Zeng contributed to analysis of data and revision of the paper. Prof. Li contributed to obtaining funding and the design of model. Dr. Wan contributed to collection of data. Prof. Chen contributed to obtaining funding and provision of clinical data. Mrs. Ouyang, Wang, and Zhao contributed to collection of data. Prof. Peng and Li are the guarantors for the overall content.


  1. 1.
    International Agency for Research on Cancer. Stomach cancer incidence, mortality and prevalence worldwide in 2008 summary. Accessed 10 July 2012.
  2. 2.
    National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: gastric cancer guideline 2011 (Chinese). Accessed 10 July 2012.
  3. 3.
    National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: gastric cancer guideline 2010 (Chinese). Accessed 10 July 2012.
  4. 4.
    Bang Y-J, Kim Y-W, Yang H-K, et al. Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial. Lancet. 2012;379:315–21.PubMedCrossRefGoogle Scholar
  5. 5.
    National Bureau of Statistics of the People’s Republic of China. Gross domestic product. Accessed 6 July 2012.
  6. 6.
    Hunan Pharmaceutical. Medicine prices. Accessed 18 July 2012.
  7. 7.
    WHO. Life table. Accessed 14 July 2012.
  8. 8.
    Briggs A, Claxton K, Sculpher M. Decision modeling for health economic evaluation. New York: Oxford University Press; 2006.Google Scholar
  9. 9.
    Wu B, Ye M, Chen H, et al. Costs of trastuzumab in combination with chemotherapy for HER2-positive advanced gastric or gastroesophageal junction cancer: an economic evaluation in the Chinese context. Clin Ther. 2012;34(2):468–79.PubMedCrossRefGoogle Scholar
  10. 10.
    Liubao P, Xiaomin W, Chongqing T, et al. Cost-effectiveness analysis of adjuvant therapy for operable breast cancer from a Chinese perspective: doxorubicin plus cyclophosphamide versus docetaxel plus cyclophosphamide. Pharmacoeconomics. 2009;27(10):873–86.PubMedCrossRefGoogle Scholar
  11. 11.
    Wu B, Dong B, Xu Y, et al. Economic evaluation of first-line treatments for metastatic renal cell carcinoma: a cost-effectiveness analysis in a health resource-limited setting. PLoS One. 2012;7(3):e32530.PubMedCrossRefPubMedCentralGoogle Scholar
  12. 12.
    Guangzhou Biaodian Medical Information. Report on antitumor (anticancer) drug market in 2010. Accessed 2 July 2012.
  13. 13.
    The People’s Bank of China. Exchange rate. Accessed 17 July 2012.
  14. 14.
    Wilson D, Hiller L, Geh JI. Review of second-line chemotherapy for advanced gastric adenocarcinoma. Clin Oncol (R Coll Radiol). 2005;17:81–9.CrossRefGoogle Scholar
  15. 15.
    Munene G, Francis W, Garland SN, et al. The quality of life trajectory of resected gastric cancer. J Surg Oncol. 2012;105:337–41.PubMedCrossRefGoogle Scholar
  16. 16.
    Sakamaki H, Ikeda S, Yajima S, et al. Cost-utility analysis of the oral fluoropyrimidine S-1 versus conventional intravenous chemotherapy in advanced or recurrent gastric cancer. Open Health Serv Policy J. 2009;2:26–33.CrossRefGoogle Scholar
  17. 17.
    International Society for Pharmacoeconomics and Outcomes Research. Chinese guidelines for pharmacoeconomic evaluations (2011). Accessed 5 July 2012.
  18. 18.
    Yang T, Shen X, Tang X, et al. Phase II trial of oxaliplatin plus oral capecitabine as first-line chemotherapy for patients with advanced gastric cancer. Tumori. 2011;97(4):466–72.PubMedGoogle Scholar
  19. 19.
    Liu C, Sun Q, Hang X, et al. Multicenter phase II study of capecitabine plus oxaliplatin as a first-line therapy in Chinese patients with advanced gastric cancer. Anticancer Drugs. 2008;19(8):825–31.PubMedCrossRefGoogle Scholar
  20. 20.
    Park YH, Lee JL, Ryoo BY, et al. Capecitabine in combination with oxaliplatin (XELOX) as a first-line therapy for advanced gastric cancer. Cancer Chemother Pharmacol. 2008;61(4):623–9.PubMedCrossRefGoogle Scholar
  21. 21.
    Jatoi A, Murphy BR, Foster NR, the North Central Cancer Treatment Group, et al. Oxaliplatin and capecitabine in patients with metastatic adenocarcinoma of the esophagus, gastroesophageal junction and gastric cardia: a phase II study from the North Central Cancer Treatment Group. Ann Oncol. 2006;17:29–34.PubMedCrossRefGoogle Scholar
  22. 22.
    National Comprehensive Cancer Network. NCCN guidelines: gastric cancer. Accessed 5 July 2012.
  23. 23.
    Chen XZ, Jiang K, Hu JK, et al. Cost-effectiveness analysis of chemotherapy for advanced gastric cancer in China. World J Gastroenterol. 2008;14(17):2715–22.PubMedCrossRefPubMedCentralGoogle Scholar
  24. 24.
    Yeh JM, Kuntz KM, Ezzati M, et al. Exploring the cost-effectiveness of Helicobacter pylori screening to prevent gastric cancer in China in anticipation of clinical trial results. Int J Cancer. 2009;124(1):157–66.PubMedCrossRefPubMedCentralGoogle Scholar
  25. 25.
    Yip WCM, Hsiao WC, Chen W, et al. Early appraisal of China’s huge and complex health-care reforms. Lancet. 2012;379:833–42.PubMedCrossRefGoogle Scholar
  26. 26.
    Bang YJ, Van Cutsem E, Feyereislova A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet. 2010;376:687–97.PubMedCrossRefGoogle Scholar
  27. 27.
    Sakuramoto S, Sasako M, Yamaguchi T, et al. Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine. N Engl J Med. 2007;357:1810–20.PubMedCrossRefGoogle Scholar
  28. 28.
    Sasako Mitsuru, Sakuramoto Shinichi, Katai Hitoshi, et al. Five-year outcomes of a randomized phase III trial comparing adjuvant chemotherapy with S-1 versus surgery alone in stage II or III gastric cancer. J Clin Oncol. 2011;29(33):4387–93.PubMedCrossRefGoogle Scholar

Copyright information

© Springer International Publishing Switzerland 2013

Authors and Affiliations

  • Tan Chongqing
    • 1
    • 2
  • Peng Liubao
    • 1
    • 2
    Email author
  • Zeng Xiaohui
    • 2
  • Li Jianhe
    • 1
  • Wan Xiaomin
    • 1
  • Chen Gannong
    • 3
  • Wang Siying
    • 2
  • Ouyang Lihui
    • 2
  • Zhao Ziying
    • 2
  1. 1.Department of PharmacyThe Second Xiangya Hospital of Central South UniversityChangshaPeople’s Republic of China
  2. 2.School of Pharmaceutical SciencesCentral South UniversityChangshaPeople’s Republic of China
  3. 3.Department of SurgeryThe Second Xiangya Hospital of Central South UniversityChangshaPeople’s Republic of China

Personalised recommendations